Hemoglobin Hasharon (α247 his(CD5)β2): a hemoglobin found in low concentration

S. Charache; A. M. Mondzac; U. Gessner

doi:10.1172/JCI106041

¹Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Find articles by Charache, S. in: JCI | PubMed | Google Scholar

¹Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Find articles by Mondzac, A. in: JCI | PubMed | Google Scholar

¹Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Find articles by Gessner, U. in: JCI | PubMed | Google Scholar

Published in Volume 48, Issue 5 on May 1, 1969
J Clin Invest. 1969;48(5):834–847. https://doi.org/10.1172/JCI106041.
© 1969 The American Society for Clinical Investigation

Published May 1, 1969 - Version history

Hemoglobin Hasharon (α₂^{47 his}(CD5)β₂) was found to comprise only 16-19% of hemolysates of carriers. These heterozygotes appeared to have mild, compensated, hemolytic anemia. Hb Hasharon was more heat-labile than hemoglobins A, S, or C. Its specific activity was higher than that of Hb A after administration of ⁵⁹Fe to two carriers. When hemoglobin synthesis by bone marrow cells was studied in vitro, about 18% of incorporated leucine appeared in the Hb Hasharon fraction. It is suggested that Hb Hasharon is unstable in vivo, and that mild hemolytic anemia and a relatively small decrease in its concentration in hemolysates result from its denaturation within red cells. Decreased synthesis, which appears to be the major cause of the small amount of abnormal hemoglobin, may protect heterozygotes from clinically significant hemolytic anemia.

Images.